Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Kymera Therapeutics announced positive results from its BroADen Phase 1b trial of KT-621, a novel oral STAT6 degrader, in patients with moderate-to-severe atopic dermatitis. The data showed significant biological and clinical improvements with a favorable safety profile. Ongoing Phase 2b trials in atopic dermatitis and asthma are expected to provid…